About: High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma   Goto Sponge  NotDistinct  Permalink

An Entity of Type : owl:Thing, within Data Space : data.idref.fr associated with source document(s)

AttributesValues
Author
Bibliographic Citation
  • Delfau-Larue Marie-Hélène, Klapper Wolfram, Berger Françoise, Jardin Fabrice, Brière Josette, Salles Gilles, Casasnovas Olivier, Feugier Pierre, Haioun Corinne, Ribrag Vincent, Thieblemont Catherine, Unterhalt Michael, Dreyling Martin, Macintyre Elizabeth, Pott Christiane, Hermine Olivier, Hoster Eva. High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. Blood, American Society of Hematology, 2015, 126 (5), pp.604-611. ⟨10.1182/blood-2015-02-628792⟩
  • Delfau-Larue Marie-Hélène, Klapper Wolfram, Berger Françoise, Jardin Fabrice, Brière Josette, Salles Gilles, Casasnovas Olivier, Feugier Pierre, Haioun Corinne, Ribrag Vincent, Thieblemont Catherine, Unterhalt Michael, Dreyling Martin, Macintyre Elizabeth, Pott Christiane, Hermine Olivier, Hoster Eva . High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma . Blood, 2015, 126 (5), pp.604-611 . ⟨10.1182/blood-2015-02-628792⟩
Title
  • High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma
dc:date
  • 2015
Digital Object Identifier (DOI)
  • 10.1182/blood-2015-02-628792
Faceted Search & Find service v1.13.91 as of Aug 16 2018


Alternative Linked Data Documents: ODE     Content Formats:       RDF       ODATA       Microdata      About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data]
OpenLink Virtuoso version 07.20.3229 as of May 14 2019, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (70 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software